While many fitness for work programs include some form of drug testing, often the focus is on the presence of illicit drugs, due to their known effects on driving performance. However the effects of prescription drugs is often overlooked, despite potentially having similar risk profiles.
Although a complex area, given the interaction of individual privacy restrictions, fatigue management and other considerations, this presentation will present some metrics for assessing risk as well as tools for risk reduction in the workplace.
This webinar will be presented by:
- Adjunct Associate Professor David Allen, Managing Director At Drug And Alcohol Solutions Australia (DASA)
With over 30 years’ experience in occupational medicine, Dr Allen is a leading authority on managing drugs and alcohol at work. His in-depth knowledge of drugs and drug use combined with his practical workplace focus make this an informative and compelling session not to be missed.
- Andrew Leibie, Commercial Manager At Healius Pathology
Andrew Leibie has been working as a scientist and business professional in the field of workplace drug testing for over 2 decades. Andrew has presented and published a number of papers on aspects of workplace drug testing in both national and international drug testing forums. He is a member of the Forensic and Clinical Toxicologists Association, as well as a member of the Royal College of Pathologists (RCPA) Quality Assurance Program expert working panel for Toxicology.